Market Cap 26.04B
Revenue (ttm) 2.38B
Net Income (ttm) 770.95M
EPS (ttm) N/A
PE Ratio 9.34
Forward PE 9.01
Profit Margin 32.42%
Debt to Equity Ratio 0.92
Volume 2,179,799
Avg Vol 3,869,286
Day's Range N/A - N/A
Shares Out 577.24M
Stochastic %K 72%
Beta 0.42
Analysts Strong Sell
Price Target $51.43

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 2:07 PM
$RPRX RSI: 83.57, MACD: 1.3636 Vol: 1.88, MA20: 43.08, MA50: 40.69 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
smartkarma
smartkarma Feb. 20 at 7:04 PM
$RPRX | Royalty Pharma’s Long Game—Synthetic Royalties, Portfolio Resilience, and Scalable Returns! "Royalty Pharma reported a strong set of results for the fourth quarter and full year 2025, reflecting continued momentum in portfolio receipts,..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/royalty-pharma-s-long-game-synthetic-royalties-portfolio-resilience-and-scalable-returns
0 · Reply
StockBraker
StockBraker Feb. 19 at 11:53 AM
$RPRX Mission accomplished
0 · Reply
d_risk
d_risk Feb. 11 at 11:35 PM
$RPRX - Royalty Pharma plc - 10K - Updated Risk Factors RPRX flags broader biopharma headwinds (trial failures, approvals, pricing, patents, safety) plus sharper leverage and liquidity constraints, higher concentration and competition for royalties, limited product visibility, expanded regulatory, IP, macro, and tax exposures, new key-person and organizational risks, and added legal, ESG, cybersecurity, and AI uncertainties. #PharmaceuticalRoyalties #OperationalRisk #MarketVolatility #FinancialLeverage #RegulatoryRisk #BiopharmaSector #ESGConcerns #IPChallenges #LiquidityConstraints #RegulatoryRisks 🟢 Added 🟠 Removed https://dev.d-risk.ai/RPRX/10-K/2026-02-11
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 11 at 12:44 PM
$RPRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.38 down -19.15% YoY • Reported revenue of $622M up 4.78% YoY • Royalty Pharma expects full year 2026 Portfolio Receipts to be between $3.28B and $3.43B, reflecting an expected Royalty Receipts growth of 3% to 8%.
0 · Reply
mikesterz7
mikesterz7 Feb. 11 at 12:41 PM
$RPRX 🚨 Adjusted Cash Flow (Non-GAAP): $1.46 per share. Total Revenue: $622 million (GAAP). Adjusted Revenue: $874 million. Net Income: $214 million. Earnings Beat: The reported adjusted EPS of $1.46 exceeded the consensus estimate of $1.33. Revenue Growth: The $622 million revenue marked a 4.7% increase from the $594 million reported in the same period last year. Full Year 2025 and Outlook Full Year 2025 Revenue: $3.25 billion. Full Year 2025 Net Income: $771 million. 2026 Outlook: The company projects full-year 2026 revenue in the range of $3.28 billion to $3.43 billion. Key Developments Dividend Increase: The company announced a 6.8% increase in its quarterly dividend to $0.235 per Class A share for Q1 2026. Deal Activity: The company experienced high deal velocity, announcing $4.7 billion in new transactions during 2025. Share Repurchases: In 2025, the company repurchased $1.2 billion in shares (35 million shares).
0 · Reply
JFDI
JFDI Feb. 10 at 4:46 PM
Clearly, alerts were not set. $RPRX
0 · Reply
victorgn
victorgn Feb. 6 at 6:31 PM
$RPRX 48.71 $ target
0 · Reply
StockBraker
StockBraker Feb. 4 at 8:36 PM
$RPRX New 52 week high reached today. Personally looking for $45.
0 · Reply
DappDelta
DappDelta Feb. 4 at 11:08 AM
$RPRX is a royalty-based pharma model providing non-correlated cash flows but is dependent on a few key blockbuster drugs.
0 · Reply
Latest News on RPRX
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 4:44 PM EST - 11 days ago

Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript


Royalty Pharma Reports Q4 and Full Year 2025 Results

Feb 11, 2026, 7:00 AM EST - 12 days ago

Royalty Pharma Reports Q4 and Full Year 2025 Results


Royalty Pharma Announces Dividend Increase

Jan 9, 2026, 8:30 AM EST - 6 weeks ago

Royalty Pharma Announces Dividend Increase


Royalty Pharma to Present at Upcoming Investor Conferences

Nov 26, 2025, 8:15 AM EST - 3 months ago

Royalty Pharma to Present at Upcoming Investor Conferences


Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 1:01 PM EST - 3 months ago

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript


Royalty Pharma Reports Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 3 months ago

Royalty Pharma Reports Third Quarter 2025 Results


Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 4 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend


Royalty Pharma: Investor Day Upside

Sep 12, 2025, 3:54 PM EDT - 5 months ago

Royalty Pharma: Investor Day Upside


Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)

Sep 11, 2025, 8:16 PM EDT - 5 months ago

Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)


Royalty Pharma: Keep Delivering, Buy Confirmed

Aug 9, 2025, 6:23 AM EDT - 7 months ago

Royalty Pharma: Keep Delivering, Buy Confirmed


Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:52 PM EDT - 7 months ago

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript


Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Royalty Pharma Reports Second Quarter 2025 Results


Royalty Pharma Declares Third Quarter 2025 Dividend

Jul 18, 2025, 8:15 AM EDT - 7 months ago

Royalty Pharma Declares Third Quarter 2025 Dividend


OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 2:07 PM
$RPRX RSI: 83.57, MACD: 1.3636 Vol: 1.88, MA20: 43.08, MA50: 40.69 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
smartkarma
smartkarma Feb. 20 at 7:04 PM
$RPRX | Royalty Pharma’s Long Game—Synthetic Royalties, Portfolio Resilience, and Scalable Returns! "Royalty Pharma reported a strong set of results for the fourth quarter and full year 2025, reflecting continued momentum in portfolio receipts,..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/royalty-pharma-s-long-game-synthetic-royalties-portfolio-resilience-and-scalable-returns
0 · Reply
StockBraker
StockBraker Feb. 19 at 11:53 AM
$RPRX Mission accomplished
0 · Reply
d_risk
d_risk Feb. 11 at 11:35 PM
$RPRX - Royalty Pharma plc - 10K - Updated Risk Factors RPRX flags broader biopharma headwinds (trial failures, approvals, pricing, patents, safety) plus sharper leverage and liquidity constraints, higher concentration and competition for royalties, limited product visibility, expanded regulatory, IP, macro, and tax exposures, new key-person and organizational risks, and added legal, ESG, cybersecurity, and AI uncertainties. #PharmaceuticalRoyalties #OperationalRisk #MarketVolatility #FinancialLeverage #RegulatoryRisk #BiopharmaSector #ESGConcerns #IPChallenges #LiquidityConstraints #RegulatoryRisks 🟢 Added 🟠 Removed https://dev.d-risk.ai/RPRX/10-K/2026-02-11
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 11 at 12:44 PM
$RPRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.38 down -19.15% YoY • Reported revenue of $622M up 4.78% YoY • Royalty Pharma expects full year 2026 Portfolio Receipts to be between $3.28B and $3.43B, reflecting an expected Royalty Receipts growth of 3% to 8%.
0 · Reply
mikesterz7
mikesterz7 Feb. 11 at 12:41 PM
$RPRX 🚨 Adjusted Cash Flow (Non-GAAP): $1.46 per share. Total Revenue: $622 million (GAAP). Adjusted Revenue: $874 million. Net Income: $214 million. Earnings Beat: The reported adjusted EPS of $1.46 exceeded the consensus estimate of $1.33. Revenue Growth: The $622 million revenue marked a 4.7% increase from the $594 million reported in the same period last year. Full Year 2025 and Outlook Full Year 2025 Revenue: $3.25 billion. Full Year 2025 Net Income: $771 million. 2026 Outlook: The company projects full-year 2026 revenue in the range of $3.28 billion to $3.43 billion. Key Developments Dividend Increase: The company announced a 6.8% increase in its quarterly dividend to $0.235 per Class A share for Q1 2026. Deal Activity: The company experienced high deal velocity, announcing $4.7 billion in new transactions during 2025. Share Repurchases: In 2025, the company repurchased $1.2 billion in shares (35 million shares).
0 · Reply
JFDI
JFDI Feb. 10 at 4:46 PM
Clearly, alerts were not set. $RPRX
0 · Reply
victorgn
victorgn Feb. 6 at 6:31 PM
$RPRX 48.71 $ target
0 · Reply
StockBraker
StockBraker Feb. 4 at 8:36 PM
$RPRX New 52 week high reached today. Personally looking for $45.
0 · Reply
DappDelta
DappDelta Feb. 4 at 11:08 AM
$RPRX is a royalty-based pharma model providing non-correlated cash flows but is dependent on a few key blockbuster drugs.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 3 at 1:01 PM
$RPRX Share Price: $42.33 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $2.72 – $3.35 Target Zone: $4.68 – $5.73 Potential Upside: 63% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 4:07 AM
$RPRX Current Stock Price: $42.33 Contracts to trade: $42.5 RPRX Feb 20 2026 Call Entry: $0.80 Exit: $1.47 ROI: 83% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 28 at 5:03 PM
$RPRX Share Price: $40.43 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.78 – $5.85 Potential Upside: 77% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 22 at 8:00 PM
$RPRX Share Price: $39.75 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $2.08 – $2.57 Target Zone: $3.33 – $4.07 Potential Upside: 51% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 4:50 PM
$TEVA and $RPRX team up for a promising vitiligo treatment! Teva’s latest $500M funding agreement with Royalty Pharma boosts its TEV-’408 development, targeting a massive unmet need in the autoimmune space. Early phase Ib data offers initial validation of IL-15 as a promising therapeutic target for diseases like vitiligo. Find out how this strategic move could reshape TEVA's future 👉 https://www.zacks.com/stock/news/2815809/teva-signs-deal-with-rprx-to-accelerate-development-of-vitiligo-drug?cid=sm-stocktwits-2-2815809-body-28451&ADID=SYND_STOCKTWITS_TWEET_2_2815809_BODY_28451
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 3:50 PM
$TEVA lands a big funding win — vitiligo drug push just sped up Teva signed a $500M funding deal with $RPRX to accelerate development of its vitiligo candidate, TEV-'408, while retaining global commercial control — a notable balance of capital and control. Get the full breakdown on what this deal means for TEVA 👉 https://www.zacks.com/stock/news/2815809/teva-signs-deal-with-rprx-to-accelerate-development-of-vitiligo-drug?cid=sm-stocktwits-2-2815809-teaser-28434&ADID=SYND_STOCKTWITS_TWEET_2_2815809_TEASER_28434
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 12 at 1:53 PM
Why Is TEVA Stock Rising Pre-Market Today? $TEVA $RPRX https://stocktwits.com/news/equity/markets/why-is-teva-stock-rising-pre-market-today/cmUaGqaR4EB
0 · Reply
Quantumup
Quantumup Jan. 12 at 11:29 AM
Leerink reit'd $ANAB OP/$64 after $RPRX & $TEVA announced a funding agreement of up to $500 million to accelerate devt of TEV-53408, TEVA's IL-15 monoclonal antibody. We view this transaction as incrementally positive for ANAB, as it further validates the IL-15/CD122 axis and should benefit investor perception of this therapeutic class, including ANB033. Under the agreement, RPRX will provide $75 million to fund a Ph2b program, with an option to invest an additional $425 million to support later-stage development. Recall TEVA is advancing TEV-53408 in two ongoing studies: a Ph2 trial in celiac disease (CeD, N=48, est. PC Sep 2026, NCT06807463) and a Ph1 trial in vitiligo (N=36, est. PC May 2026, NCT06625177). TEV-53408 is designed with a 38-day half-life and is intended for quarterly or less frequent dosing. TEVA anticipates sharing results from TEV-53408 trials during 2026. ANB033 is a CD122 antagonist which inhibits both the IL15 and IL2 signaling pathways. Maintain OP on ANAB shares.
0 · Reply
carlwilliambrown
carlwilliambrown Jan. 12 at 10:17 AM
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 11 at 10:56 PM
$RPRX $TEVA Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo "Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 "
0 · Reply
TechridyStocks
TechridyStocks Jan. 7 at 5:06 PM
$RPRX bullish over $41.01
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 31 at 4:01 PM
Since 1/1/13 we're unaware of any synergistic value opportunity that appears to exist between $INCY & $SNDX The opportunity appears so massive it could almost be a disservice to INCY shareholders to not buy SNDX (again could be). See the attached FY29/FY30 revenue multiples, after Jakafi patent exp INCY has an existing portfolio of 3 FDA approved hematology focused therapies, incl Niktimvo. There's virtually no incremental costs to INCY to add SNDX's Revuforj to their global comm'l & distribution systems. See our previous post where we calculated the NPV of the amounts due from INCY to SNDX to be just under $2B (using a 14% discount rate & $RPRX published Niktimvo revenue estimates thru FY38) INCY had ~$3B cash @ 9/30/25. INCY expects to earn interest @ 4% at best. INCY's $3B cash is 1.6X SNDX's market cap @ $21/share. Again our NPV calc used a 14% rate of return INCY's CEO was on SNDX's BOD through June 2025 Of course we could also be wrong about INCY/SNDX This is not investment advice
1 · Reply